# Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

> **NCT03738943** · EARLY_PHASE1 · COMPLETED · sponsor: **Colorado State University** · enrollment: 9 (actual)

## Conditions studied

- Receptor Blockade

## Interventions

- **DRUG:** Adenosine Triphosphate
- **DRUG:** Acetylcholine
- **DRUG:** Sodium Nitroprusside
- **DRUG:** Adenosine Diphosphate
- **DRUG:** Adenosine Monophosphate
- **DRUG:** Uridine Triphosphate
- **DRUG:** Adenosine
- **DRUG:** Vitamin B 6
- **DRUG:** Pyridoxal 5'-Phosphate

## Key facts

- **NCT ID:** NCT03738943
- **Lead sponsor:** Colorado State University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-07
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-06-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2021-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03738943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03738943, "Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03738943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*